FRI-378 - Proof of efficacy for Seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis non-responsive to ursodeoxycholic acid: results of an international Phase 2 randomised controlled clinical study

Autor: Hirschfield, G.M., Galambos, M.R., Bowlus, C.L., Swain, M.G., Doerffel, Y., Steinberg, A.S., Varga, M., Choi, Y.-J., Martin, R.L., Chera, H., McWherter, C.A., Boudes, P.F., Jones, D.
Zdroj: In Journal of Hepatology 2017 66(1) Supplement:S357-S357
Databáze: ScienceDirect
Externí odkaz: